SCHEMBL14956460

SCHEMBL14956460

NC(=O)c1ncc(NC2CCNC2)nc1Nc1cnc2ccccc2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SYK P43405 10/20 0.47
▸ KCNH2 Q12809 6/20 0.47
▸ MAPK1 P28482 4/20 0.47
▸ MAPK3 P27361 3/20 0.47
▸ AURKB Q96GD4 3/20 0.47
▸ CHEK1 O14757 3/20 0.46
▸ BTK Q06187 3/20 0.46
▸ LCK P06239 2/20 0.46
▸ PRKD2 Q9BZL6 3/20 0.45
▸ RPS6KB1 P23443 2/20 0.45
▸ CDC7 O00311 1/20 0.45
▸ PLK4 O00444 1/20 0.45
▸ PDPK1 O15530 1/20 0.45
▸ DAPK3 O43293 1/20 0.45
▸ DYRK3 O43781 1/20 0.45
▸ JAK2 O60674 1/20 0.45
▸ ROCK2 O75116 1/20 0.45
▸ RPS6KA5 O75582 1/20 0.45
▸ PRKD3 O94806 1/20 0.45
▸ MAP4K4 O95819 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14956458 1.00 SYK (0.47) SYKKCNH2MAPK1MAPK3AURKB
SCHEMBL14955850 0.95 CHEK1 (0.53) SYKKCNH2MAPK1MAPK3AURKB
SCHEMBL14955848 0.95 CHEK1 (0.53) SYKKCNH2MAPK1MAPK3AURKB
SCHEMBL14956010 0.89 SYK (0.43) SYKKCNH2MAPK1MAPK3AURKB
SCHEMBL14956013 0.89 SYK (0.43) SYKKCNH2MAPK1MAPK3AURKB
SCHEMBL14955589 0.89 SYK (0.52) SYKKCNH2MAPK1MAPK3AURKB
SCHEMBL14956315 0.89 SYK (0.52) SYKKCNH2MAPK1MAPK3AURKB
SCHEMBL14955592 0.89 SYK (0.52) SYKKCNH2MAPK1MAPK3AURKB
SCHEMBL14956380 0.86 LCK (0.49) SYKKCNH2MAPK1CHEK1BTK
SCHEMBL14956378 0.86 LCK (0.49) SYKKCNH2MAPK1CHEK1BTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9359308-B2 Pyrazine kinase inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2016-06-07 — — US disclosed
US-8877760-B2 Substituted pyrazine-2-carboxamide kinase inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2014-11-04 — — US disclosed
US-20140309209-A1 Pyrazine Kinase Inhibitors ALEXION PHARMACEUTICALS, INC. 2014-10-16 — — US disclosed
EP-2782579-A1 PYRAZINE KINASE INHIBITORS Portola Pharmaceuticals, Inc. (US) 2014-10-01 — — EP disclosed
WO-2013078466-A1 PYRAZINE KINASE INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2013-05-30 — — WO disclosed
US-20130131040-A1 PYRAZINE KINASE INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2013-05-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130131040-A1 PYRAZINE KINASE INHIBITORS SYK, ZAP70, LCK SYK 1/4885KCNH2 1944/4885MAPK1 364/4885
US-20140309209-A1 Pyrazine Kinase Inhibitors SYK, ZAP70, LCK SYK 1/4885KCNH2 1944/4885MAPK1 364/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback